Skip to main content
Top
Published in: Rheumatology International 4/2004

01-07-2004 | Original Article

Serum oxidized low-density lipoproteins in rheumatoid arthritis

Authors: Seong-Ho Kim, Chang-Keun Lee, Eun Young Lee, So Yeon Park, You Sook Cho, Bin Yoo, Hee-Bom Moon

Published in: Rheumatology International | Issue 4/2004

Login to get access

Abstract

Objective

The aim of this study was to measure serum oxidized low-density lipoprotein (Ox-LDL) levels in patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) and to identify any association with clinical variables.

Methods

We studied 126 female patients (27 with active RA, 27 with inactive RA, 72 with SLE). One hundred fifteen age-matched healthy women (76 for RA, 39 for SLE) with no clinical or laboratory evidence of disease served as normal controls. Serum Ox-LDL levels were measured with a commercial enzyme-linked immunosorbent assay kit (Mercodia, Sweden).

Results

The serum Ox-LDL levels were significantly higher in patients with active RA (P<0.05) or SLE (P<0.01) than age-matched controls and significantly higher in patients with active RA than with inactive RA (P<0.01). The levels of serum total cholesterol and LDL were significantly lower in patients with RA than in age-matched controls (P<0.01). There was no correlation among serum Ox-LDL levels and inflammatory markers (erythrocyte sedimentation rate, C-reactive protein) or rheumatoid factors in patients with RA.

Conclusions

Compared with healthy women, those with SLE or active RA had increased serum Ox-LDL levels, which may contribute to the increased risk of cardiovascular disease in this patient group.
Literature
1.
go back to reference Symmons DP, Jones MA, Scott DL, Prior P (1998) Long-term mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 25:1072–1077PubMed Symmons DP, Jones MA, Scott DL, Prior P (1998) Long-term mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 25:1072–1077PubMed
2.
go back to reference Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA (1994) The mortality of rheumatoid arthritis. Arthritis Rheum 37:481–494PubMed Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA (1994) The mortality of rheumatoid arthritis. Arthritis Rheum 37:481–494PubMed
3.
go back to reference Wolfe F, Freundlich B, Straus WL (2003) Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 30:36–40PubMed Wolfe F, Freundlich B, Straus WL (2003) Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 30:36–40PubMed
4.
go back to reference Banks M, Flint J, Bacon PA, Kitas GD (2000) Rheumatoid arthritis is an independent risk factor for ischemic heart disease. [Abstract.] Arthritis Rheum 43 [Suppl 9]:S385 Banks M, Flint J, Bacon PA, Kitas GD (2000) Rheumatoid arthritis is an independent risk factor for ischemic heart disease. [Abstract.] Arthritis Rheum 43 [Suppl 9]:S385
5.
go back to reference Gabriel SE, Crowson CS, O’Fallon WM (1999) Comorbidity in arthritis. J Rheumatol 26:2475–2479PubMed Gabriel SE, Crowson CS, O’Fallon WM (1999) Comorbidity in arthritis. J Rheumatol 26:2475–2479PubMed
6.
go back to reference Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA, Jansen-McWilliams L (1997) Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145:408–415PubMed Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA, Jansen-McWilliams L (1997) Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145:408–415PubMed
7.
go back to reference Del Rincón I, Williams K, Stern MP, Freeman GL, Escalante A (2001) High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44:2737–2745PubMed Del Rincón I, Williams K, Stern MP, Freeman GL, Escalante A (2001) High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44:2737–2745PubMed
8.
go back to reference Tontonoz P, Nagy L, Alvarez JGA, Thomazy VA, Evans RM (1998) PPARg promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93:241–252PubMed Tontonoz P, Nagy L, Alvarez JGA, Thomazy VA, Evans RM (1998) PPARg promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93:241–252PubMed
9.
go back to reference Mertens A, Holvoet P (2001) Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J 15:2073–2084CrossRefPubMed Mertens A, Holvoet P (2001) Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J 15:2073–2084CrossRefPubMed
10.
go back to reference Memon RA, Staprans I, Noor M, Holleran WM, Uchida Y, Moser AH (2000) Infection and inflammation induce LDL oxidation in vivo. Arterioscler Thromb Vasc Biol 20:1536–1542PubMed Memon RA, Staprans I, Noor M, Holleran WM, Uchida Y, Moser AH (2000) Infection and inflammation induce LDL oxidation in vivo. Arterioscler Thromb Vasc Biol 20:1536–1542PubMed
11.
go back to reference Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T (1993) Cross-reaction between antibodies to oxidized low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 341:923–925PubMed Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T (1993) Cross-reaction between antibodies to oxidized low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 341:923–925PubMed
12.
go back to reference Amengual O, Atsumi T, Khamashta MA, Tinahones F, Hughes GR (1997) Autoantibodies against oxidized low-density lipoprotein in antiphospholipid syndrome. Br J Rheumatol 36:964–968CrossRefPubMed Amengual O, Atsumi T, Khamashta MA, Tinahones F, Hughes GR (1997) Autoantibodies against oxidized low-density lipoprotein in antiphospholipid syndrome. Br J Rheumatol 36:964–968CrossRefPubMed
13.
go back to reference James MJ, van Reyk D, Tye KA, Dean RT, Cleland LG, Barter PJ (1998) Low density lipoprotein of synovial fluid in inflammatory joint disease is mildly oxidized. Lipid 33:1115–1121 James MJ, van Reyk D, Tye KA, Dean RT, Cleland LG, Barter PJ (1998) Low density lipoprotein of synovial fluid in inflammatory joint disease is mildly oxidized. Lipid 33:1115–1121
14.
go back to reference Winyard PG, Tatzber F, Esterbauer H, Kus ML, Blake DR, Morris CJ (1993) Presence of foam cells containing oxidized low density lipoprotein in the synovial membrane from patients with rheumatoid arthritis. Ann Rheum Dis 52:677–680PubMed Winyard PG, Tatzber F, Esterbauer H, Kus ML, Blake DR, Morris CJ (1993) Presence of foam cells containing oxidized low density lipoprotein in the synovial membrane from patients with rheumatoid arthritis. Ann Rheum Dis 52:677–680PubMed
15.
go back to reference Dai L, Zhang Z, Winyard PG, Gaffney K, Jones H, Blake DR (1997) A modified form of low-density lipoprotein with increased electronegative charge is present in rheumatoid arthritis synovial fluid. Free Radical Bio Med 22:705–710CrossRef Dai L, Zhang Z, Winyard PG, Gaffney K, Jones H, Blake DR (1997) A modified form of low-density lipoprotein with increased electronegative charge is present in rheumatoid arthritis synovial fluid. Free Radical Bio Med 22:705–710CrossRef
16.
go back to reference Paimela L, Helve T, Leirisalo-Repo M, Vaarala O, Alfthan G, Palosuo T (1996) Clinical significance of antibodies against oxidized low density lipoprotein in early RA. Ann Rheum Dis 55:558–563PubMed Paimela L, Helve T, Leirisalo-Repo M, Vaarala O, Alfthan G, Palosuo T (1996) Clinical significance of antibodies against oxidized low density lipoprotein in early RA. Ann Rheum Dis 55:558–563PubMed
17.
go back to reference Wållberg-Jonsson S, Cvetkovic JT, Sundqvist K-G, Lefvert AK, Rantapää-Dahlqvist S (2002) Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol 29:875–882PubMed Wållberg-Jonsson S, Cvetkovic JT, Sundqvist K-G, Lefvert AK, Rantapää-Dahlqvist S (2002) Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol 29:875–882PubMed
18.
go back to reference Cvetkovic JT, Wållberg-Jonsson S, Ahmed E, Rantapää-Dahlqvist S, Lefvert AK (2002) Increased levels of autoantibodies against copper-oxidized low density lipoprotein, malondialdehyde-modified low density lipoprotein and cardiolipin in patients with rheumatoid arthritis. Rheumatology 41:988–995CrossRefPubMed Cvetkovic JT, Wållberg-Jonsson S, Ahmed E, Rantapää-Dahlqvist S, Lefvert AK (2002) Increased levels of autoantibodies against copper-oxidized low density lipoprotein, malondialdehyde-modified low density lipoprotein and cardiolipin in patients with rheumatoid arthritis. Rheumatology 41:988–995CrossRefPubMed
19.
go back to reference Holvoet P, Donck J, Landeloos M, Brouwers E, Luijtens K, Arnout J (1996) Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thromb Haemost 76:663–669PubMed Holvoet P, Donck J, Landeloos M, Brouwers E, Luijtens K, Arnout J (1996) Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thromb Haemost 76:663–669PubMed
20.
go back to reference Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA (1996) Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 7:69–76PubMed Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA (1996) Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 7:69–76PubMed
21.
go back to reference Gitlin JD (1988) Transcriptional regulation of ceruloplasmin gene expression during inflammation. J Biol Chem 263:6281–6287PubMed Gitlin JD (1988) Transcriptional regulation of ceruloplasmin gene expression during inflammation. J Biol Chem 263:6281–6287PubMed
22.
go back to reference Chisolm GM, Hazen SL, Fox PL, Cathcart MK (1999) The oxidation of lipoproteins by monocytes and macrophages. J Biol Chem 274:25959–25962CrossRefPubMed Chisolm GM, Hazen SL, Fox PL, Cathcart MK (1999) The oxidation of lipoproteins by monocytes and macrophages. J Biol Chem 274:25959–25962CrossRefPubMed
23.
go back to reference Kunitake ST, Jarvis MR, Hamilton RI, Kane JP (1992) Binding of transition metals by apolipoprotein A-1 containing plasma lipoproteins: inhibition of oxidation of low density lipoproteins. Proc Natl Acad Sci U S A 89:6993–6997PubMed Kunitake ST, Jarvis MR, Hamilton RI, Kane JP (1992) Binding of transition metals by apolipoprotein A-1 containing plasma lipoproteins: inhibition of oxidation of low density lipoproteins. Proc Natl Acad Sci U S A 89:6993–6997PubMed
24.
go back to reference Barnum-Huckins KM, Martinez AO, Rivera EV, Adrian EK Jr, Herbert DC, Weaker FJ (1997) A comparison of suppression of human transferrin synthesis by lead and lipopolysaccharide. Toxicology 118:11–22CrossRefPubMed Barnum-Huckins KM, Martinez AO, Rivera EV, Adrian EK Jr, Herbert DC, Weaker FJ (1997) A comparison of suppression of human transferrin synthesis by lead and lipopolysaccharide. Toxicology 118:11–22CrossRefPubMed
25.
go back to reference Rantapää-Dahlqvist S, Wållberg-Jonsson S, Dahlën G (1991) Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis 50:366–368PubMed Rantapää-Dahlqvist S, Wållberg-Jonsson S, Dahlën G (1991) Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis 50:366–368PubMed
26.
go back to reference Park YB, Lee SK, Lee WK (1999) Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 26:1701–1704PubMed Park YB, Lee SK, Lee WK (1999) Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 26:1701–1704PubMed
27.
go back to reference Situnayake RD, Kitas G (1997) Dyslipidemia and rheumatoid arthritis. Ann Rheum Dis 56:341–342PubMed Situnayake RD, Kitas G (1997) Dyslipidemia and rheumatoid arthritis. Ann Rheum Dis 56:341–342PubMed
28.
go back to reference Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PA (1990) Cholesterol lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids. Am J Med 89:322–326PubMed Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PA (1990) Cholesterol lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids. Am J Med 89:322–326PubMed
29.
go back to reference Borba EF, Bonfa E (1997) Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 6:533–539PubMed Borba EF, Bonfa E (1997) Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 6:533–539PubMed
30.
go back to reference Svenungsson E, Jensen-Urstad K, Heimbürger M, Silveira A, Hamsten A, de Faire U (2001) Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104:1887–1893PubMed Svenungsson E, Jensen-Urstad K, Heimbürger M, Silveira A, Hamsten A, de Faire U (2001) Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104:1887–1893PubMed
Metadata
Title
Serum oxidized low-density lipoproteins in rheumatoid arthritis
Authors
Seong-Ho Kim
Chang-Keun Lee
Eun Young Lee
So Yeon Park
You Sook Cho
Bin Yoo
Hee-Bom Moon
Publication date
01-07-2004
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 4/2004
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-003-0358-4

Other articles of this Issue 4/2004

Rheumatology International 4/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.